Perinatal depression – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Perinatal depression – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Using Estradiol to Prevent Postpartum Depression in Women with a History of the Condition https://clinicaltrials.eu/trial/study-on-using-estradiol-to-prevent-postpartum-depression-in-women-with-a-history-of-the-condition/ Wed, 29 Apr 2026 15:05:26 +0000 https://clinicaltrials.eu/trial/study-on-using-estradiol-to-prevent-postpartum-depression-in-women-with-a-history-of-the-condition/ The study focuses on postpartum depression, a type of depression that can occur after childbirth. The treatment being studied is a short-term use of the female sex hormone estradiol, which is delivered through a transdermal patch called Vivelle Dot. This patch releases a controlled amount of estradiol into the body over a 24-hour period. The study also involves a placebo, which is a substance with no active medication, to compare the effects of estradiol.

The purpose of the study is to see if using estradiol shortly after giving birth can help prevent depressive episodes in women who have previously experienced postpartum depression. Participants will receive either the estradiol patch or the placebo for a short period, from the day of birth up to 21 days postpartum. The study will monitor the participants for signs of depression from two weeks to six months after giving birth.

This research aims to provide insights into whether estradiol can be an effective strategy to prevent postpartum depression in women who are at high risk. By comparing the outcomes between those using the estradiol patch and those using the placebo, the study seeks to determine the potential benefits of this hormone treatment in managing postpartum mental health.

]]> Study on Treating Anemia After Cesarean with Ferric Carboxymaltose or Oral Iron in Women with Moderate Iron Deficiency Anemia https://clinicaltrials.eu/trial/study-on-treating-anemia-after-cesarean-with-ferric-carboxymaltose-or-oral-iron-in-women-with-moderate-iron-deficiency-anemia/ Wed, 29 Apr 2026 14:30:25 +0000 https://clinicaltrials.eu/trial/study-on-treating-anemia-after-cesarean-with-ferric-carboxymaltose-or-oral-iron-in-women-with-moderate-iron-deficiency-anemia/ This clinical trial is focused on studying the treatment of anemia in women who have undergone a caesarean delivery. Anemia is a condition where there is a lower than normal number of red blood cells, which can lead to fatigue and weakness. The study will compare the effects of two types of iron treatments: intravenous (IV) iron and oral iron. The IV iron used in this study is called Ferinject, which contains ferric carboxymaltose. The oral iron treatments include Timoferol in two forms: a coated tablet containing dried ferrous sulfate and a hard capsule containing both ascorbic acid and ferrous sulfate.

The purpose of the study is to assess how these treatments affect the prevalence of postpartum depression at 8 weeks after delivery in women with moderate iron deficiency anemia following a caesarean section. Postpartum depression is a type of depression that can occur after childbirth, affecting a mother’s mood and overall well-being. The study will involve monitoring the participants over a period of 8 weeks to observe any changes in their condition and to evaluate the effectiveness of the treatments.

Participants will receive either the IV iron or one of the oral iron treatments, or a placebo, and their health will be monitored throughout the study. The study aims to provide valuable insights into the best treatment options for managing anemia and reducing the risk of postpartum depression in new mothers. The findings could help improve care for women experiencing these conditions after a caesarean delivery.

]]>